Triple Hair Group develops innovative treatments for men and women suffering from androgenic alopecia, including its flagship prescription product, Therapy-07. The company also markets drug-free patented OTC products for preventing hair loss and regaining hair density under the RIZN™ brand for men and Plenty Natural™ for women. Led by CEO and President Jean-Philippe Gravel, Triple Hair aims to provide clinically proven, accessible hair-regrowth solutions across early- and later-stage hair loss. It has Health Canada approval to begin Phase III clinical trials for Therapy-07 and is awaiting approvals in other jurisdictions, notably the US and Europe. The company intends to use recent funding to accelerate those Phase III trials and to prepare to begin trials in several countries. Triple Hair is based in Montréal, Canada.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2024